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Abstract 
Angiogenesis is a fundamental requirement for tumor growth and therefore it is a primary 
target for anti-cancer therapy. Molecular imaging of angiogenesis may provide novel oppor-
tunities for early diagnostic and for image-guided optimization and management of therapeutic 
regimens. Here we reviewed the advances in targeted imaging of key biomarkers of tumor 
angiogenesis, integrins and receptors for vascular endothelial growth factor (VEGF). Tracers 
for targeted imaging of these biomarkers in different imaging modalities are now reasonably 
well-developed and PET tracers for integrin imaging are currently in clinical trials. Molecular 
imaging of longitudinal responses to anti-angiogenic therapy in model tumor systems revealed 
a complex pattern of changes in targeted tracer accumulation in tumor, which reflects 
drug-induced tumor regression followed by vascular rebound. Further work will define the 
competitiveness of targeted imaging of key angiogenesis markers for early diagnostic and 
image-guided therapy. 
Key words: tumor angiogenesis, molecular imaging, integrins, VEGF receptors, anti-angiogenic 
therapy. 
Introduction 
This article is intended as a review of recent ad-
vances  in  molecular  imaging  of  key  biomarkers  of 
tumor  angiogenesis  and  their  responses  to  an-
ti-angiogenic therapy. Although tumor neovasculari-
zation combines two distinct processes, angiogenesis 
and vasculogenesis, the term “angiogenesis” is often 
used interchangeably with the term “neovasculariza-
tion” (1, 2). Under normal circumstances, neovascu-
larization  occurs  during  embryonic  development, 
wound  healing,  and  development  of  the  corpus  lu-
teum. However, neovascularization takes place in a 
large  number  of  pathologies,  such  as  solid  tumor 
growth,  various  eye  diseases,  chronic  inflammatory 
states  including  development  of  atherosclerotic 
plaques, and ischemic injuries (3).  
To focus on oncology, angiogenesis is an early 
hallmark  of  tumor  growth  and  therefore  molecular 
imaging of angiogenesis is expected to help in early 
diagnosis of primary tumor and emerging metastatic 
lesions. On the other hand, recognition that inhibition 
of  neovascularization  may  delay  progression  and 
perhaps  even  starve  tumor  to  death  resulted  in 
enormous research and drug development efforts by 
countless academic and industrial groups. As a result 
of these efforts, several therapeutic agents, commonly 
known as anti-angiogenic drugs, have been approved 
for  clinical  use  and  hundreds  of  late-stage  clinical 
trials of anti-angiogenic drugs and combination reg-
iments are currently in progress (1-9). Unfortunately, 
the  approved  anti-cancer  anti-angiogenic  drugs 
bevacizumab  (Avastin,  Genentech/Roche),  sunitinib 
(Sutent,  Pfizer),  sorafenib  (Nexavar,  Bayer),  pazo-
panib  (Votrient,  GlaxoSmithKline)  as  well  as  many 
exploratory  drugs,  are  effective  only  in  relatively 
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small  and  unpredictable  subsets  of  patients,  while 
treatment can result in serious side effects (1-9). These 
shortcomings,  as  well  as  very  high  cost  of  an-
ti-angiogenic drugs ($50-100K/patient/year), prevent 
their broad acceptance by regulatory authorities and 
by private and national insurance providers. There-
fore, there is an urgent need in imaging-based meth-
odologies  that  can  early  and  reliably  identify  re-
sponders and could be used for image-guided opti-
mization  and  “personalization”  of  anti-angiogenic 
regimens.  
Key biomarkers for imaging angiogenesis 
Research in the last few decades established sig-
nificant  differences  in  organization  and  molecular 
composition of angiogenic tumor vs. quiescent normal 
vasculature. Several proteins are expressed at higher 
levels on the surface of endothelial cells in angiogenic 
vasculature  and  might  serve  as  suitable  targets  for 
imaging.  Importantly,  unlike  biomarkers  on  tumor 
cells,  these  targets  are  accessible  directly  from  the 
bloodstream and therefore they can be imaged with-
out problems associated with tracer extravasation and 
tumor  penetration.  One  group  of  angiogenic  bi-
omarkers  is  integrins,  particularly  αvβ3  and  αvβ5 
integrins.  Integrins  are  transmembrane  proteins  in-
volved in cell growth, survival, adhesion, and motili-
ty,  serving  as  receptors  for  proteins  in  extracellular 
matrix  (ECM)  and  certain  immunoglobulin  super-
family proteins (10-12, Fig. 1). However, in addition to 
endothelial cells in angiogenic vasculature, integrins 
are  also  expressed  on  many  tumor  cells,  and  this 
should be taken into account in interpretation of any 
integrin-related  experimental  results.  There  are 
twenty  four  αβ  heterodimeric  integrins  formed  by 
eighteen α and eight β subunits; many integrins rec-
ognize  certain  exposed  peptide  sequences.  One  ex-
ample is RGD (arginine-glycine-aspartic acid) that is 
present  in  many  ECM  and  some  secreted  proteins, 
such as fibronectin, vitronectin, fibrinogen, laminin, 
collagen,  Von  Willebrand  factor,  osteoponin,  and 
trombospondin.  
 
 
Figure 1. Integrins assembles in focal adhesions (a-c) and ‘integrate’ signals from the extracellular matrix (ECM) to the intracellular 
cytoskeleton (11). Many integrins that are not bound to the extracellular matrix (ECM) are present on the cell surface in an inactive 
conformation (a), Recruitment of intracellular proteins induces conformational transition in integrins (b), which unmask the ligand-binding 
site, allowing the integrin to bind specific ECM molecules (c). The maturation of focal adhesions involves clustering of active, ligand-bound 
integrins and the assembly of a multiprotein complex that is capable of linking integrins to the actin cytoskeleton and communicating with 
signalling pathways. 
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Figure 2. VEGF signaling inhibitors and their targets (13). The VEGF family of ligands (VEGFA, PlGF, VEGFB, VEGFC, and 
VEGFD) bind to their cognate receptors (VEGFR1; blue, VEGFR2; grey, VEGFR3; green) as indicated (arrows). Several different VEGF 
antagonists interfere with binding of VEGF ligands on the extracellular domain (Bevacizumab, VEGF-Trap, Veglin, IMC-18F1, Ramuci-
umab/CDP791), or compete for ATP-binding to the intracellular kinase domain (axitinib, brivanib, cediranib, linifanib, pazopanib, sorafenib, 
sunitinib, tivozanib, vandetanib, vatalanib). VEGFRs are shown with their extracellular domain organized in immunoglobulin-like loops 
(circles, labeled 1–7) and with intracellular split tyrosine kinase domain (squares). VEGFR1 is critical in inflammatory angiogenesis and 
VEGFR3 in lymphangiogenesis. VEGFR2 transduces signals to proliferation, migration, survival and vascular permeability (through path-
ways indicated in boxes) resulting in angiogenesis. 
 
Interaction of integrins with RGD, or other lig-
ands, induces assembly of signaling complexes, which 
promote various changes in cellular behavior (Fig. 1). 
Although  several  drugs  targeting  integrins  are  cur-
rently in clinical trials, the role of integrins in regu-
lating angiogenesis is not yet fully understood; it is 
complex- and, apparently, context-dependent (10-12). 
However,  enhanced  expression  of  αvβ3  and  αvβ5 
integrins  in  tumor  vasculature,  as  well  as  multiple 
avenues  for  engineering  and  optimization  of 
RGD-based  tracers  for  different  imaging  modalities 
provided a very strong impetus for developing integ-
rin-targeting tracers for molecular imaging.  
Another group of biomarkers overexpressed in 
tumor vasculature is the receptors for vascular endo-
thelial growth factor (VEGF). VEGF is the crucial reg-
ulator of angiogenesis; and its action on endothelial 
cells  is  mediated  by  two  tyrosine  kinase  receptors, 
VEGFR-1  and  VEGFR-2,  primarily  VEGFR-2  (13-15) 
(Fig. 2). VEGFR-2 is expressed predominantly on en-
dothelial  cells,  although  it  may  be  also  present  on 
other  cells.  Immunohistochemical  analysis  indicates 
that a subset of endothelial cells at the sites of angio-
genesis, particularly in the tumor growth areas, express 
significantly higher levels of VEGFR-2 than quiescent 
endothelial cells, making it a highly suitable target for 
diagnostic molecular imaging. 
Because of its profound physiological significance, 
the VEGF/VEGFR pathway is the major target for an-
ti-angiogenic  drugs.  The  first  blockbuster  drugs  tar-
geting VEGFR have already been approved by FDA 
for treatment of several cancers with ~275,000 new US 
cases per year (8-9). The potential of these drugs is 
enormous,  as  judged  by  several  hundreds  of 
US-registered  Phase  III  clinical  trials 
(www.clinicaltrials.gov)  for  all  major  cancers  with Theranostics 2012, 2(5) 
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annual 12 million new cases, worldwide. However, as 
indicated above, responses of individual patients to 
anti-angiogenic drugs and combination therapies are 
complex  and  unpredictable  (3-9).  In  this  respect, 
monitoring the prevalence of VEGF receptors in re-
sponse  to  VEGF/VEGFR  targeting  drugs  might  be 
useful for treatment regimen optimization.  
In  addition  to  integrins  and  VEGF  receptors, 
several other proteins are selectively overexpressed in 
tumor vasculature, such as matrix metalloproteinases 
(MMPs), prostate-specific membrane antigen (PSMA), 
endoglin  (CD105),  endosialin  (CD248/TEM1), 
E-selectin, components of ECM, such as extra domain 
B of fibronectin and extra domain C of tenascin (16). 
Furthermore,  the  use  of  high  throughput  experi-
mental  methods,  as  well  as  powerful  bioinformatic 
methods, suggest that other targets could be discov-
ered and exploited as imaging biomarkers (17). 
Molecular tracers for imaging key bi-
omarkers of angiogenesis 
Development of RGD-based tracers for imag-
ing  integrins.  The  first  RGD-based  tracers,  cy-
clo(-Arg-Gly-Asp-D-Tyr-Val-)  and  cyclo(-Arg-Gly- 
Asp-D-Phe-Tyr-)  that  utilized  cyclized  RGD-based 
peptides radiolabeled with 125I have been described in 
1999 (18). These tracers were used for imaging integ-
rins in three different tumor models (melanoma M21 
or  mammary  carcinoma  MaCaF  in  nude  mice  and 
osteosarcoma  in  BALB/c  mice).  Since  that  time,  al-
most  300  publications  described  continuous  im-
provement in tracer design for every imaging modal-
ity and expansion of its field of use. One key advance 
was  introduction  of  polyethyleneglycol,  sugar,  or 
hydrophilic  amino  acid  residues  in  the  RGD-based 
tracers to improve pharmacokinetics, to provide facile 
opportunities  for  direct  radiohalogenation,  particu-
larly with 18F, or conjugation of chelators for loading 
with  various  radionuclides  (12),  or  preparation  of 
RGD-driven nano- and microparticle for multimodal 
imaging  and  drug  delivery.  As  a  result  of  these 
chemical  advances,  RGD-based  tracers  for  PET, 
SPECT, MRI, fluorescent optical imaging, ultrasound 
imaging, and photoacoustic imaging were developed 
and validated in animal models (12, 19-22). Another 
key advance was multimerization of several copies of 
RGD sequences in a single construct in order to in-
crease the affinity of the tracers to targeted cells and 
enhance  integrin-mediated  internalization  (23-29). 
Particularly promising is recent development of var-
ious RGD-driven multimodality nano- and micropar-
ticles  combining,  for  example,  MRI  and  fluorescent 
contrast agents (30-35), or combining contrast agents 
and drugs (36-39). It should be noted that most pub-
lished  reports  describe  the  kinetic  of  clearance  of 
RGD-based tracers from tumor and other organs, not 
the kinetics of accumulation. Detailed kinetic analysis 
of biodistribution and clearance with 64Cu-RGD tracer 
indicates that it was cell surface binding, rather than 
cellular  internalization  that  led  to  accumulation  of 
tracer  at  early  time  points  (40).  Nevertheless,  pro-
longed  kinetics  of  intracellular  accumulation  of 
RGD-tracers,  at  least  for  tumors  that  express 
RGD-binding  integrins  on  tumor  cells,  was  demon-
strated with fluorescent probes that are unquenched 
only in intracellular environment (34, 41). As judged 
by accumulation of RGD-based tracers in tumor, they 
successfully  compete  with  endogenous  integrin  lig-
ands.  However,  their  accumulation  in  the  tumor 
might  be  modulated  not  only  by  the  prevalence  of 
integrins on endothelial or tumor cells, but also by the 
changes  in  prevalence  of  multiple  RGD-containing 
ligands. In general, RGD-based tracers are considered 
safe; however, in at least one publication, evidence of 
tumor-promoting  activity  of  tracer  amount  of 
RGD-containing constructs was reported (42).  
Integrin  imaging  and  therapy  monitoring.  So 
far, there are only few publications that describe the 
use  of  RGD-driven  contrast  agents  for  monitoring 
anti-cancer chemotherapy. Jung et al (43) reported the 
use of a SPECT tracer glucosamino 99mTc-D-c(RGDfK) 
for monitoring the effects  of paclitaxel treatment in 
two murine subcutaneous tumor models, RR1022 rat 
fibrosarcoma in Balb/c nude mice and mouse Lewis 
lung carcinoma (LLC) in C57BL6 mice. Intraperitoneal 
paclitaxel  therapy  (40  mg/kg  a  total  of  6  doses  at 
2-day intervals) caused statistically significant inhibi-
tion  of  tumor  growth  and  ~30%  decrease  in  tracer 
uptake, however a positive correlation between tracer 
uptake and αv integrin prevalence in tumor was not 
particularly strong (r=0.44, p<0.05).  
Palmowski et al (44) monitored the effects of the 
potent  MMP  inhibitor  AG3340  (Prinomastat)  in  a 
model of subcutaneous human squamous cell carci-
noma HaCaT-ras-A-5RT3. Microbubbles targeted by 
either  RGD  or  anti-VEGFR-2  antibody  reliably  de-
tected the dynamics of both β3 integrin and VEGFR-2 
in  the  course  of  AG3340  therapy  (150  mg/kg  i.p., 
twice a day for 7 days). In agreement with immuno-
histochemical data, the uptake of targeted microbub-
bles in treated animals was lower than in contempo-
rary  control  mice,  but  was  not  statistically  signifi-
cantly affected when analyzed longitudinally, relative 
to the uptake at the beginning of treatment. Interest-
ingly,  the  same  group  reported  that  subcutaneous 
AT-1 prostate cancers in rats treated with carbon ions 
(16 Gy) displayed significantly higher binding of in-
tegrin-targeting  microbubbles  and  upregulation  of Theranostics 2012, 2(5) 
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integrin  expression  without  significant  changes  in 
microvascular density (45). 
GE  Healthcare  group  reported  the  use  of 
18F-AH111585  (fluciclatide)  cyclic  RGD-based  PET 
tracer  (currently  in  clinical  trials)  for  evaluation  of 
responses  to  two  specific  anti-angiogenic  drugs, 
VEGFR-2  tyrosine  kinase  inhibitors  ZD4190  and 
sunitinib (46-48). Longitudinal imaging of nude mice 
bearing  subcutaneous  human  lung  adenocarcinoma 
Calu-6  indicated  that  three  days  of  treatment  with 
ZD4190 (100 mg/kg orally daily) did not affect tumor 
growth, but uptake of fluciclatide in individual mice 
decreased  31.8%  ±  4.6%,  relative  to  baseline 
pre-treatment uptake (in %ID/g) in the same animal 
(n = 10) (Fig. 3). In contrast, uptake of the tracers in 
control animals was increased by 26.9% ± 9.4%, sug-
gesting that ZD4190 causes changes in tracer uptake 
(46). However, there were no changes in the micro-
vascular density in ZD4190-treated vs. control mice, 
as measured by CD31 immunostaining. Furthermore, 
treatment of LLC tumor grown in C57BL/6 mice with 
paclitaxel (10 mg/kg i.p. daily, for 4 days) caused a 
~35%  decrease  in  average  fluciclatide  uptake  in 
treated vs control mice also without changes in the 
microvascular density. 
Longitudinal imaging of mice bearing subcuta-
neous  U87  MG  human  glioblastoma-astrocytoma 
tumors treated with sunitinib (60 mg/kg orally daily, 
two 5-day cycles with 2-day no drugs between cycles) 
also indicated a small but significant decrease in flu-
ciclatide  uptake  (13-17%),  relative  to  the  baseline 
pre-treatment level observed from Day 2 to Day 9 of 
treatment  (47).  In  contrast,  in  control  animals  there 
was a small but significant increase in tracer uptake 
relative to the baseline level. It should be noted that 
longitudinal imaging was particularly instrumental in 
this system, because control tumors grew rapidly and 
developed a necrotic core with tracer uptake concen-
trated in the outer rim of tumor, while tumor growth 
in treated animals was slow and tracer uptake was 
observed throughout the tumor. It should be noted, 
however,  that  in  sunitinib-treated  animals  the  de-
crease in tumor microvascular density by Day 13 was 
far more dramatic, ~ 73% relative to control tumors 
than the changes in tracer uptake. However, consid-
ering the different patterns of tracer uptake in control 
and treated tumors, these discrepancies are not par-
ticularly surprising. 
 
Figure 3. Representative coregistered small-animal PET and micro-CT images demonstrating 18F-AH111585 uptake at 120 min in Calu-6 
xenograft model before (A) and after (B) administration of 3 doses of vehicle control or before (C) and after (D) 3 doses of 100 mg/kg of 
ZD4190 (46). Contrast is clearly seen in Calu-6 tumors located on left shoulder region in both ZD4190-treated and vehicle control 
animals. The only additional higher activity concentration was found in bladder. In addition, 22Na fiducial markers can be seen located on 
base of imaging bed (used for PET/CT coregistration). ROI analysis for tumor uptake before ZD4190 therapy was 1.7 %ID/g, decreasing 
to 1.1 %ID/g after ZD4190 therapy. Muscle uptake was maintained at 0.5 %ID/g in pre and post-ZD4190–therapy images. For animals 
treated with vehicle control alone, ROI analysis for tumor uptake before vehicle control was 2.1 %ID/g, increasing to 2.5 %ID/g after 
therapy. Muscle uptake was maintained at 0.3 %ID/g in pre- and posttherapy images. Theranostics 2012, 2(5) 
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Dumont  et  al  (49)  reported  the  use  of 
[64Cu]DOTA-cyclo-(Arg-Gly-Asp-DPhe-Lys)  PET 
tracer for evaluation of the dasatinib, an inhibitor of 
Src family and other tyrosine kinases, which is cur-
rently undergoing multiple clinical trials. This group 
used the same U87 MG tumor model and validated 
the drug activity by a decrease in immunostaining for 
phospho-FAK. After three days of treatment (72 or 95 
mg/kg  orally  daily),  RGD  tracer  uptake  in  treated 
animals vs. control was decreased by 39% in the 72 
mg/kg dose group and 59% in the 95 mg/kg dose 
group. However, tumor growth, 18F-FDG uptake, the 
levels of vascularization (as judged by CD31 staining), 
and αvβ3 levels were not affected at that time, making 
interpretation of the changes in tracer uptake rather 
difficult.  
 Finally,  Yang  et  al  (50)  used  18F-FPPRGD2 
(2-fluoropropionyl  labeled  PEGylated  dimeric  RGD 
peptide [PEG3-E{c(RGDyk)}2]) PET tracer to evaluate 
responses  to  3-day  treatment  with  ZD4190  (100 
mg/kg, daily, orally) in human MDA-MB-435 tumor 
grown in nude mouse fat pad. It should be noted that 
for many years MDA-MB-435 were considered to be 
derived  from  human  breast  carcinoma,  but  recent 
analyses indicated that currently available cells are, 
most likely, derivative of human M14 melanoma cell 
line  (see,  http://www.lgcstandards-atcc.org/ 
MisidentifiedCellLines/tabid/1171/Default.aspx).  In 
MDA-MB-435 model, unlike in Calu-6 tumors (46), a 
3-day treatment with ZD4190 virtually blocked tumor 
growth for 7 days, after which tumor growth resumed 
with  the  rate  similar  to  that  in  control  animals. 
Somewhat  surprisingly,  PET  imaging  with  18F-FDG 
indicated that glucose metabolism was not affected by 
tumor  growth  inhibition,  while  PET  imaging  with 
18F-FLT indicated that cell proliferation was inhibited 
on  Day  1  and  3,  but  returned  to  the  pre-treatment 
baseline  by  Day  7.  The  longitudinal  changes  in  the 
uptake of 18F-FPPRGD2 PET tracer displayed a similar 
pattern, a decrease of ~17.5% and 28.5% relative to the 
pretreatment baseline on Day 1 and 3, and return to 
the  baseline  at  Day  7.  Interestingly,  expression  of 
human αvβ3 integrins on MDA-MB-435 appears to be 
decreased by ~30% and 46% on Day 1 and 3 of the 
treatment but return to the baseline by Day 7. Taken 
together, the initial experience with RGD-based trac-
ers  for  monitoring  chemotherapy  in  animal  tumor 
models indicates that it is possible to detect small but 
significant drug-induced decreases in tracer uptake. 
However, the connections between timing and mag-
nitude  of  these  changes  and  alterations  in  tumor 
vasculature  appears  to  be  system-  and 
drug-dependent,  reflecting  drug-induced  complex 
changes  in  integrin  prevalence,  internalization,  and 
occupancy  by  host  ligands.  Obviously,  further  re-
search is necessary to untangle these processes and 
assess their effects on longitudinal changes in integrin 
imaging with RGD-based tracers. 
Clinical trials with RGD-based tracers. To date, 
several clinical trials with RGD-based tracers are ei-
ther completed or in progress.  18F-galacto-RGD PET 
tracer was tested in cancer patients (51-58). The tracer 
is safe with an overall patient exposure similar to that 
from  18F-FDG imaging.  18F-galacto-RGD PET uptake 
was  highly  variable  between  patients  and  between 
different tumor lesions in the same patient, as well as 
highly heterogeneous within individual lesions. Im-
portantly,  18F-galacto-RGD  readily  accumulated  in 
many, but not all lesions that were identified by other 
imaging  modalities.  Some  lesions  negative  for 
18F-galacto-RGD uptake were confirmed to be nega-
tive for αvβ3 presence. Interestingly, there was a poor 
correlation  between  18F-FDG  and  18F-galacto-RGD 
uptake  in  individual  lesions,  suggesting  that  each 
tracer can provide independent information for stag-
ing and molecular analysis of tumor lesions. 
Several reports described the use of RGD-based 
99mTc-NC100692 tracer developed by  GE Healthcare 
for detection of primary breast cancer lesions (59, 60) 
and metastatic lesions in patients with lung or breast 
cancer  (61).  The  tracer  was  safe  and  well  tolerated. 
Scintigraphy with 99mTc-NC100692 identified 19 out of 
22 primary lesions (86%), which range in size from 5 
mm to 40 mm. Importantly, six benign lesions were 
not identified with 99mTc-NC100692, whereas fine be-
nign  changes,  4  fibrocystic  changes  and  1  infected 
cyst,  were  identified.  However,  only  infected  cyst 
displayed focal accumulation of tracer similar to that 
in  malignant  lesions,  while  uptake  in  fibrocystotic 
lesions  was  diffused,  not  focal,  and  readily  distin-
guished from malignant lesions. In addition, imaging 
of axillary region detected lymph node metastases >20 
mm,  but  not  small  <5  mm  non-palpable  ones. 
Screening for metastatic lesions in breast cancer pa-
tients (n=10) 99mTc-NC100692 scintigraphy detected 1 
of 7 liver, 4 of 5 lung, 8 of 17 bone, and 1 of 1 brain 
metastases.  Screening  for  metastatic  lesions  in  lung 
cancer patients were 0 of 2 liver, 17 of 18 lung, 2 of 2 
bone, and 7 of 9 brain metastases. Authors concluded 
that 99mTc-NC100692 scintigraphy could be useful for 
detection of lung and brain metastases, but not bone 
and liver metastases. 
Imaging  with  18F-AH111585  (fluciclatide)  PET 
tracer  (62)  was  used  in  7  patients  with  metastatic 
breast cancer (3 patients with metastases only in the 
liver, 2 with metastases only in the lung, 1 with me-
tastases only in bone and 1 with metastases in bone 
and a supraclavicular lymph node). In these patients Theranostics 2012, 2(5) 
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PET  imaging  identified  all  18  lesions  that  were  de-
tected  by  CT  (Fig.  4).  Interestingly,  PEGylated  flu-
ciclatide accumulated in lesions gradually, reaching a 
plateau by 50-60 min and displaying apparently irre-
versible  binding  to  its  target.  In  contrast, 
18F-galacto-RGD accumulated faster but binding ap-
pears to be reversible (55).  
Finally,  a  group  from  Stanford  University  de-
scribed the results  of a pilot study of  18F-FPPRGD2 
PET  (2-fluoropropionyl  labeled  PEGylated  dimeric 
RGD  peptide  [PEG3-E{c(RGDyk)}2])  PET  tracer  in 
healthy volunteers and reported favorable dosimetry 
and pharmacokinetics for this tracer (63).  
Taken together, these initial clinical studies es-
tablished that RGD-based nuclear tracers are safe and 
can be used for detection of primary and metastatic 
lesions.  Further  studies  will  indicate  whether  and 
under what circumstances these molecular tracers are 
superior to other diagnostic imaging procedures and 
whether they can be used for image-guided therapy 
with anti-angiogenic or other therapeutic regimens.  
Development of tracers for imaging VEGF re-
ceptors. Several types of targeting moieties are cur-
rently  used  for  development  of  tracers  for  imaging 
VEGF  receptors  in  angiogenic  vasculature:  various 
versions of human VEGF itself, anti-VEGFR antibody, 
VEGFR-binding  peptides,  and  small  molecule  com-
pounds. The VEGF-based tracers are particularly at-
tractive  for  potential  clinical  development  because 
they expected to be less immunogenic and are rapidly 
internalized  via  VEGF-induced  VEGFR-mediated 
endocytosis,  providing  for  intracellular  tracer  accu-
mulation.  On  the  other  hand,  unless  specifically 
re-engineered,  VEGF-based  tracers  would  bind  to 
both VEGFR-1 and VEGFR-2, and also there is a risk 
of affecting host vasculature, even at low concentra-
tions of VEGF.  
 
 
 
 
 
Figure  4.  PET  imaging  with  18F-AH111585  in  cancer  patients  (62).  Left  Panel,  PET  images  showing  localization  of 
18F-AH111585 in patient 2 with grade II invasive ductal breast carcinoma in sagittal (A) and transverse (B) views. PET images of patient 1 
with SCF in coronal (C) and transverse (D) views. Right Panel, 18F-AH111585 PET of metastatic lesions and corresponding CT images 
showing increased signal in periphery of lesions in patient with lung and pleural metastases (E), intralesion heterogeneity of uptake within 
pleural metastasis in PET image, which was not demonstrated as necrosis on corresponding CT section (G), and liver metastases imaged 
as hypointense lesions because of high background signal (F). High uptake in spleen is possibly due to blood pooling. See also color bar for 
PET images. 
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Three groups reported on iodination of recombi-
nant VEGF121 and VEGF165 with 123I or 125I and the use 
these tracers in mouse tumor models (64, 65) and even 
in human patients in Europe (66, 67). However, un-
certain  VEGF  functional  activity,  potential  dehalo-
genation of radioactive iodine, and a very high liver 
uptake (44 %ID/g and 32 %ID/g, respectively) made 
further development of these iodinated tracers highly 
unlikely.  Several  64Cu  PET  tracers  based  on 
His-tagged  recombinant  VEGF121,  which  was  ran-
domly  derivatized  with  DOTA  on  lysine  residues, 
have been developed at Stanford University and used 
for imaging VEGF receptors in angiogenic vasculature 
in tumor and ischemia models (68-72). This group also 
described a VEGF-driven multimodality tracer based 
on DOTA-derivatized quantum dots randomly con-
jugated to VEGF enabling both PET and near-infrared 
imaging (73).  
Since VEGF121 is a dimeric protein with 14 lysine 
residues, random conjugation of radionuclide chela-
tors  inevitably  generates  a  mixture  of  tracers  with 
different properties. To avoid these problems, several 
VEGF-based tracers designed for site-specific conju-
gation  of  contrast  agents  or  radionuclide  chelators 
have been described in the last few years. Two groups 
used  111In  for  site-specific  radiolabeling  of  either 
VEGF121 with DTPA conjugated to Cys-116 or trans-
ferring  moiety  in  transferin-VEGF165  fusion  protein 
(74,  75).  VEGF121  was  expressed  with  Avi-tag  for 
site-specific  biotinylation  followed  by  coupling  to 
streptavidin-IRDye800  for  near-infrared  fluorescent 
imaging (76).  
Several site-specifically derivatized VEGF-based 
tracers were developed using dimeric VEGF121 (77, 78) 
or a more robust and versatile single-chain VEGF de-
rivative,  named  scVEGF  (79).  ScVEGF  (Fig.  5,  Left 
Panel) is composed of two fused 3-112 amino acid (aa) 
VEGF fragments, lacking a C-terminal pro-angiogenic 
domain, and is expressed with an N-terminal 15-aa 
cysteine-containing  tag  (Cys-tag)  for  site-specific 
conjugation  of  various  payloads  (80).  Cys-tagged 
scVEGF  was  site-specifically  derivatized  with  a 
PEGylated chelator DOTA for PET imaging with 64Cu 
(79) and 68Ga (81, 82), 99mTc chelator HYNIC (succin-
imidyl  6-hydrazinopyridine-3-carboxylate  hydro-
chloride), it was directly radiolabeled with  99mTc for 
SPECT imaging (78, 79, 83), or near-infrared fluores-
cent dyes for fluorescent imaging (77, 79), and cou-
pled with microbubbles for ultrasound imaging (84). 
Advantageously,  site-specific  conjugation  of  even 
large payloads (e.g., PEGylated chelators, liposomes, 
dendrimers) did not affect the affinity of scVEGF to 
VEGF receptors, VEGFR-mediated internalization of 
scVEGF-based conjugates, and a long-term (at least 7 
days, Fig. 6, Right Panel) retention of delivered fluo-
rescent dyes (80, 85, 86). Furthermore, recent experi-
ments indicated that scVEGF-PEG-DOTA conjugates 
do  not  stimulate  tumor  growth  even  at  cumulative 
doses that are at least an order of magnitude higher 
than those needed for imaging (87).  
 
Figure 5. Imaging VEGF receptors with scVEGF-based tracers (79). Left Panel, Targeting protein, scVEGF was engineered by 
head-to-tail fusion of two 3-112 fragments of VEGF121 and expressed with N-terminal Cys-tag for site-specific conjugation of imaging and 
therapeutic payloads. Right Panel, Long-term retention of Cy5.5 after imaging with scVEGF/Cy. 4T1luc tumor-bearing mice (n=5) were 
injected with scVEGF/Cy and imaged daily for 7 days. Fresh luciferin was injected prior to each imaging. Representative first (30 min 
post-injection) and last (7 days post-injection) NIRF and BLI images for the same mouse are presented. On merged BLI and NIRF images 
the BLI footprint is contoured in red. Note that despite an average 4.5-fold increase in the tumor size, as judged by caliper measurements 
(from 6 x 5 x 2 mm (length x width x height) to 11 x 7 x 3 mm, average measurements) and BLI footprints, the intensity and the NIRF image 
area did not change significantly (ROI area ~110,000 px, ROI intensity ~280,000). Scale bar, 1 cm. Theranostics 2012, 2(5) 
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Figure 6. Pazopanib treatment affects scVEGF/99mTc tracer uptake (85). A, Representative anterior oblique views of the tumors 
from control and treated mice reconstructed from 3-D data sets obtained in serial SPECT imaging. B. Pazopanib significantly affects tracer uptake in 
areas of maximal activity. The average activity of the upper 98th percentile of voxels (98th%) was calculated from the longitudinal SPECT imaging for 
each mouse on Day 0, 5 and 15 for treated and timed cohorts of control mice. C, Tumor weights for control and treated mice. Control, untreated 
mice. Rx, pazopanib-treated mice. 
 
 
Finally, although most VEGF-based tracers uti-
lized VEGF-A isoforms (VEGF121 or VEGF165), recent-
ly,  rat  VEGF-C  was  randomly  derivatized  with 
HYNIC, radiolabeled with  99mTc, and used for imag-
ing VEGFR-2 and VEGFR-3 in U-251 rat glioma model 
(88).  VEGF-based  tracers  are  internalized  via 
VEGFR-mediated endocytosis, as judged by accumu-
lation  and  persistence  of  fluorescent  dyes  in 
VEGFR-positive  endothelial  cell  after  injection  of 
VEGF-based fluorescent tracers in vitro and in vivo 
(79,  85,  86).  Recent  PET  kinetic  experiments  with 
scVEGF-PEG-DOTA/68Ga suggest that uptake of in-
travenously injected tracer in mouse tumors reaches 
plateau as early as 25 sec after injection, most likely 
through the first pass (82).  
There are several variables that might affect ac-
cumulation of VEGF-based tracers in tumor endothe-
lial cells, the prevalence of VEGF receptors in angio-
genic  vasculature,  the  rate  of  receptor-mediated  in-
ternalization, and the levels (systemic or local) of en-
dogenous VEGF. Another variable is the presence of 
VEGF receptors on tumor cells, which although not as 
widespread  as  the  presence  of  integrins,  might  still 
affect imaging results in some tumors. 
Several groups described contrast agents based 
on  anti-VEGFR  antibodies,  which  were  derivatized 
with IRD800 near-infrared fluorescent dye (89), cou-
pled to ultrasound microbubbles (90-92), or coupled 
to  99mTc or Cy5.5-labeled chitosan-DC101 conjugates 
(93).  Another  emerging  approach  is  to  use 
VEGFR-binding peptides multiplexed on ultrasound 
microbubbles to enhance affinity to VEGF receptors 
(94-96). Finally, several small molecule VEGFR kinase 
inhibitors have been radiolabeled with 18F and 11C for 
PET imaging (97-99) and, at least one of the resulting 
tracers demonstrated preferential accumulation at the 
outer rim of the tumor with a pattern of distribution 
which did not follow 18F-FDG uptake (98). Consider-
ing powerful techniques that are available for selec-
tion of high affinity peptides (100), various forms of 
antibodies, and new  scaffolds with variable regions 
(e.g. adnectin, ref. 101), it would be natural to expect 
that new targeting moieties for imaging VEGF recep-
tors would continue to be discovered.  Theranostics 2012, 2(5) 
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VEGFR  imaging  and  therapy  monitoring.  So 
far,  there  are  only  few  publications  that  employed 
targeted VEGFR imaging in tumor treatment setting. 
In the first reported experiments, Cys-tagged VEGF121 
was site-specifically derivatized with HYNIC, radio-
labeled  with  99mTc  and  used  as  a  SPECT  tracer  for 
imaging VEGFR in orthotopic 4T1 tumors in Balb/c 
mice  subjected  to  chemotherapy  with  cyclophos-
phphamide (78). Treatment with high dose regimen 
(CP at 150 mg/kg i.p. q.o.d., four total doses, n = 9) or 
low dose metronomic regimen (CP at 25 mg/kg i.p. 
q.d., seven total doses, n = 9) cause the same tumor 
growth inhibition and very similar decrease in tracer 
uptake  in  tumor  vasculature.  Interestingly,  neither 
regimen significantly changed microvascular density, 
as  judged  by  CD31  immunostaining,  but  both  regi-
men  depleted  VEGFR-2  overexpressing  endothelial 
cells  from  tumor  vasculature,  suggesting  that  such 
cells  are  primarily  responsible  for  uptake  of 
VEGF-based tracers.  
As indicated above, Kiessling’s group used ul-
trasound  imaging  with  microbubbles  microbubbles 
driven by anti-VEGFR-2 antibody, to monitor the ef-
fects  of  the  potent  MMP  inhibitor  AG3340  (Prino-
mastat),  using  subcutaneous  human  squamous  cell 
carcinoma HaCaT-ras-A-5RT3 grown in left hind leg 
of nude mice (44). In that model, drug-induced de-
crease in microvascular density was associated with 
upregulation of VEGFR-2 and therefore there were no 
statistically significant longitudinal changes in tracer 
binding in the course of treatment.  
The effects of sunitinib on VEGFR imaging were 
explored in 4T1 mouse  mammary breast carcinoma 
tumor grown in the right hind limb (89). In this mod-
el, 5-day sunitinib treatment inhibited tumor growth 
and caused a 40% decrease in the immunostaining of 
VEGFR-2  on  tumor  histological  sections,  although 
changes  in  microvascular  density  were  not  statisti-
cally significant, as judged by immunostaining for a 
pan-endothelial marker. To enable VEGFR imaging, 
commercially  available  anti-VEGFR-2  antibody 
(αVEGFR2ab)  that  was  randomly  derivatized  with 
IRD800  near-infrared  fluorescent  dye  and  used  for 
intravenous  injections.  The  retention  of 
NIR800-αVEGFR2ab in untreated tumors was 2.356 ± 
0.074 (n = 10) higher than in the contralateral limb, 
while for treated animals this ratio was 1.832 ± 0.1284 
(n = 9), suggesting a ~ 22% sunitinib-induced decrease 
in tracer uptake. 
The effects of another inhibitor of VEGFR tyro-
sine  kinase  activity,  PTK787  (vatalanib)  on  VEGFR 
imaging were tested in U-251 rat glioma model (88). 
At seven day after tumor implantation in the brain, 
treatment was given daily for 5 days, followed by a 
2-day break, the next cycle of 5-day daily treatment, 
and then 3-day later either MRI imaging or SPECT 
imaging  with  99mTc-HYNIC/VEGF-C  tracer.  Unex-
pectedly, such treatment regimen caused faster tumor 
growth, higher vascularization at the tumor periph-
ery, and the higher uptake of VEGFR targeting SPECT 
tracer. Interestingly, Western blot analysis indicated 
that the overall levels of VEGFR-2 and VEGFR-3 were 
lower in treated vs. control tumors. The latter finding 
might indicate that the higher tracer uptake could be 
determined by ”better” accessibility and/or internal-
ization  of  VEGFR-2  and  VEGFR-3  in  tumors  with 
drug-induced enhanced vascularization.  
Two more detailed studies of the effects of tyro-
sine kinase inhibitors on imaging VEGFR prevalence 
revealed complex time-dependent patterns (85, 86). In 
both  studies  SPECT  imaging  of  VEGFR  with 
scVEGF/99mTc tracer (single-chain VEGF directly ra-
diolabeled with  99mTc on Cys-tag) was coupled with 
immunohistochemical  analysis  of  VEGFR-2  and  a 
pan-endothelial  marker  CD31.  Importantly,  in  vitro 
experiments indicated that tyrosine kinase inhibitors 
do  not  inhibit  VEGFR-2  mediated  uptake  of 
scVEGF-based  tracer,  allowing  for  imaging  treated 
animals (85, 86). In one study (85), VEGFR was im-
aged in subcutaneous HT29 xenografts in nude mice 
treated  with  pazopanib,  an  FDA-approved  small 
molecule tyrosine kinase inhibitor targeting VEGFR, 
PDGFR  and  c-Kit  (102,  103).  In  this  model,  SPECT 
imaging and autoradiography of tumor cryosections 
indicated  that  scVEGF/99mTc  tracer  accumulated 
preferentially  at  the  tumor  periphery  (Fig.  6).  Alt-
hough tumor growth was barely affected by Day 5 of 
treatment,  non-invasive  VEGFR-2  imaging  revealed 
early, rather dramatic effects of pazopanib on tumor 
vasculature. SPECT imaging and autoradiography of 
tumor sections indicated that 5-day pazopanib treat-
ment resulted in ~3-fold decrease in tracer uptake and 
immunohistochemical  analysis  established  a  corre-
sponding  decrease  in  the  number  of 
CD31+/VEGFR-2+ endothelial cells on tumor sections. 
However, by Day 15 of continuous pazopanib treat-
ment, the tracer uptake at the tumor periphery was 
significantly  increased  relatively  5-day  time  point, 
while  immunohistochemical  analysis  indicated 
re-growth  of  tumor  vasculature  with 
CD31+/VEGFR-2+  endothelial  cells  at  the  same  pe-
ripheral regions. Importantly, these effects were ob-
served despite 2-fold inhibition of tumor growth.  
In  another  study,  SPECT  imaging  with 
scVEGF/99mTc  was  used  to  explore  the  effects  of 
sunitinib on the vasculature of orthotopic MDA231luc 
(luciferase-expressing  derivative  of  human 
MDA-MB-231 breast carcinoma cells) tumors in nude Theranostics 2012, 2(5) 
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mice  (86).  Imaging  with  scVEGF/99mTc  and  autora-
diography  of  tumor  cryosections  revealed  a  2.2-  to 
2.6-fold  decrease  in  tracer  uptake  after  four  daily 
doses of sunitinib. However, once treatment was dis-
continued, tracer uptake rapidly (3 days) increased, 
particularly at the tumor edges. Immunohistochemi-
cal analysis of VEGFR-2 and CD31 supported imaging 
findings,  revealing  the  corresponding  depletion  of 
VEGFR-2+/CD31+ endothelial cells from tumor vas-
culature  during  the  course  of  treatment,  as  well  as 
rapid re-emergence of VEGFR-2+/CD31+ vasculature 
at the tumor edges after discontinuation of treatment. 
Interestingly, resuming sunitinib treatment after the 
3-day break caused vascular regression in some, but 
not  all  mice,  suggesting  that  resistance  to  sunitinib 
might emerge quite rapidly. Of note, similar pattern 
of  vascular  regression  and  rebound  after  treatment 
with  sunitinib  was  reported  in  A2780  and  Colo205 
tumor  models,  using  PET  imaging  with 
89Zr-ranibizumab,  a  tracer  based  on  ranibizumab,  a 
monoclonal  antibody  fragment  (Fab)  derivative  of 
VEGF-neutralizing  bevacizumab,  which  is  currently 
used  to  treat  macular  degeneration,  and  whose  ac-
cumulation in tumor reflects combination of vascular 
perfusion  and  VEGF  presence  in  the  tumor  tissue 
(104). 
Taken together, initial experience with imaging 
VEGF receptors in the course of treatment indicates 
that changes in their prevalence can be detected in the 
course of vascular regression and, critically, vascular 
rebound associated with emergence of drug-resistant 
vasculature.  Somewhat  surprisingly,  despite  contin-
uous treatment with VEGFR tyrosine kinase inhibitors 
(e.g.  pazopanib,  sunitinib,  vatalanib),  drug-resistant 
vasculature still populated by endothelial cells over-
expressing  VEGFR-2,  and  receptor-mediated  endo-
cytosis continues to accumulate VEGF-tracers inside 
the targeted cells.  
As  noted  at  the  beginning  of  this  review,  the 
mechanisms  of  action  of  anti-angiogenic  drugs  that 
target the VEGF/VEGFR pathway as well as mecha-
nisms of resistance to such drugs are not fully under-
stood (1-10). These drugs, which include inhibitors of 
VEGFR kinase activity and biologics that either block 
VEGF receptors or sequester VEGF, are not cytotoxic 
or even cytostatic. The emerging consensus is that in 
tumor microenvironment these drugs induce transi-
ent regression of tumor vasculature through yet un-
known mechanisms, followed by “adaptive-invasive” 
revascularization  or  vascular  rebound,  which  may 
lead  to  enhanced  invasiveness  and  metastatic  dis-
semination  of  the  tumor  (105,  Fig.  7).  The  timing, 
magnitude,  and  significance  of  vascular  regression 
and revascularization are critical for development of 
treatment  regimens.  For  example,  regression  might 
involve so-called “normalization” of tumor vascula-
ture (106, 107), which might provide for a better de-
livery  of  chemotherapeutic  drugs  to  tumor  growth 
areas.  In  turn,  revascularization  might  also  provide 
for  better  drug  delivery,  justifying  the  combination 
regimens and particularly metronomic combinations 
(108).  On  the  other  hand,  recent  research  in  mouse 
tumor models suggested that revascularization might 
stimulate invasiveness and metastatic dissemination 
of primary tumor (105, 109). In view of these com-
plexities, there is an urgent and still unmet need in 
developing predictive biomarkers suitable for analy-
sis  of  different  stages  in  the  course  of 
VEGF/VEGFR-directed therapies (110). Since vascu-
lar  regression  and  rebound  are  associated  with  the 
complex  dynamic  changes  in  the  prevalence  of  the 
drug  target  itself,  it  is  tempting  to  speculate  that 
non-invasive  molecular  imaging  of  VEGF  receptors 
would  be  able  to  satisfy  this  need.  If  responses  of 
human vasculature follow the same pattern of vascu-
lar regression and rebound, longitudinal VEGFR im-
aging could be able to detect patients who respond to 
therapy at the early stage of treatment and then iden-
tify those patients whose VEGFR-2 expressing vascu-
lature  stop  responding  and  who  would  benefit  if 
treatment is changed. 
Clinical trials with tracers for imaging VEGF 
receptors. To the best of our knowledge there are no 
publications  on  Phase  I/II  clinical  trials  for  VEGFR 
imaging tracers. However in 2003 and 2004, Li et al 
published  two  reports  on  using  imaging  with 
123I-VEGF165 in patients with gastrointestinal tumors 
(66, 67). Intravenous injection of ~5 µg of tracer was 
well-tolerated without detectable side effects and ra-
ther heterogeneous tracer accumulation in tumor and 
metastasis was imaged at 30 min post-injection in 18 
patients  (66).  Using  CT  and  MRI  data  as  a  “gold 
standard”, in patients with pancreatic adenocarcino-
mas, primary tumors were visualized in seven of nine, 
lymph node metastases in three of four, liver metas-
tases  in  three  of  six  and  lung  metastases  in  one  of 
three.  Cholangiocarcinomas  were  visualized  by 
123I-VEGF165 imaging in one of two patients. Hepato-
cellular  carcinomas  were  visible  in  two  of  four  pa-
tients. Weakly positive scans were registered in one 
patient with abdominal schwannoma and in one pa-
tient with peritoneal carcinosis. Of note, the majority 
of  false-negative  results  were  obtained  in  patients 
with tumors and metastases with maximum median 
diameter of <2 cm. In a follow up studies in 9 patients 
with pancreatic carcinoma, majority of primary pan-
creatic  tumors  and  their  metastases  was  visualized 
using 123I-VEGF165 tracer (67). Theranostics 2012, 2(5) 
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Figure 7. Adaptive-Evasive Responses by Tumors to Antiangiogenic Therapies (105). Schematic summary of adaptive re-
sponses  to  VEGF/VEGFR  inhibitors  (and  likely  other  angiogenesis  inhibitors)  that  elicit  ‘‘evasive  resistance.’’  Tumors  respond  to 
VEGF/VEGFR pathway inhibition with tumor stasis or regression and a loss of blood vessels, but mechanisms of evasive resistance to the 
antiangiogenic treatment are then induced that can variously enable revascularization via alternative proangiogenic signals, increased local 
invasiveness, and/or enhanced distant metastasis. 
 
Conclusions 
Currently, targeted tracers for molecular imag-
ing of integrins and VEGF receptors in different mo-
dalities receptors are reasonable well-developed and 
some RGD-based tracers are already in clinical trials. 
Only  extensive  clinical  trials  can  establish  whether 
imaging with these molecular tracers would be able to 
compete with MRI, CT, or metabolic PET imaging in 
detection and staging of primary tumors and meta-
static lesions. More promising might be application of 
molecular  imaging  for  image-guided  therapy, 
whereby the effects of drugs, particularly drugs that 
specifically  targeting  integrins,  VEGF  receptors,  or 
other targets in angiogenic vasculature, are evaluated 
in  real  time  in  individual  patients.  Certainly,  this 
strategy  would  require  extensive  clinical  trials  and 
multi-disciplinary  collaborations;  however  consider-
ing ever growing demand for personalized yet not too 
expensive  medicine,  this  strategy  might  respond  to 
unmet medical needs. 
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